CNBX PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CNBX PHARMACEUTICALS INC. (CNBX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $139.72 thousand for the 12-month period ending 2024-08-31, per its 10-K filed 2025-12-01.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-12-01
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-08-31 was $34.98K, a 0.00% change year-over-year.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-05-31 was $34.80K, a 0.51% decline year-over-year.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-02-29 was $34.98K, a 0.01% increase year-over-year.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-11-30 was $34.98K, a 53.71% decline year-over-year.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $139.72K, a 22.58% decline from fiscal 2023.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $180.48K, a 75.24% decline from fiscal 2022.
- CNBX PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $728.87K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-08-31 | $34.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-01 | $69.77K derived: sum of 2 quarters · filed 2025-12-01 | $104.75K derived: sum of 3 quarters · filed 2025-12-01 | $139.72K 10-K · filed 2025-12-01 |
| 2024-05-31 | $34.80K 10-Q · filed 2025-07-14 | $69.77K derived: sum of 2 quarters · filed 2025-07-14 | $104.75K 10-Q · filed 2025-07-14 | $139.72K derived: sum of 4 quarters · filed 2025-07-14 |
| 2024-02-29 | $34.98K 10-Q · filed 2025-04-14 | $69.95K 10-Q · filed 2025-04-14 | $104.92K derived: sum of 3 quarters · filed 2025-04-14 | $139.90K derived: sum of 4 quarters · filed 2025-04-14 |
| 2023-11-30 | $34.98K 10-Q · filed 2025-01-13 | $69.95K derived: sum of 2 quarters · filed 2025-01-13 | $104.92K derived: sum of 3 quarters · filed 2025-01-13 | $139.90K derived: sum of 4 quarters · filed 2025-01-13 |
| 2023-08-31 | $34.98K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-29 | $69.95K derived: sum of 2 quarters · filed 2024-11-29 | $104.92K derived: sum of 3 quarters · filed 2024-11-29 | $180.48K 10-K · filed 2024-11-29 |
| 2023-05-31 | $34.98K 10-Q · filed 2024-07-15 | $69.95K derived: sum of 2 quarters · filed 2024-07-15 | $145.50K 10-Q · filed 2024-07-15 | $238.79K derived: sum of 4 quarters · filed 2024-07-15 |
| 2023-02-28 | $34.97K 10-Q · filed 2024-04-16 | $110.53K 10-Q · filed 2024-04-16 | $203.81K derived: sum of 3 quarters · filed 2024-04-16 | $308.74K derived: sum of 4 quarters · filed 2024-04-16 |
| 2022-11-30 | $75.56K 10-Q · filed 2024-01-12 | $168.84K derived: sum of 2 quarters · filed 2024-01-12 | $273.76K derived: sum of 3 quarters · filed 2024-01-12 | $378.69K derived: sum of 4 quarters · filed 2024-01-12 |
| 2022-08-31 | $93.28K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-30 | $198.21K derived: sum of 2 quarters · filed 2023-11-30 | $303.13K derived: sum of 3 quarters · filed 2023-11-30 | $728.87K 10-K · filed 2023-11-30 |
| 2022-05-31 | $104.93K 10-Q · filed 2023-07-14 | $209.85K derived: sum of 2 quarters · filed 2023-07-14 | $635.59K 10-Q · filed 2023-07-14 | |
| 2022-02-28 | $104.92K 10-Q · filed 2023-04-14 | $530.66K 10-Q · filed 2023-04-14 | ||
| 2021-11-30 | $425.74K 10-Q · filed 2022-01-13 |